To date, the only possible curative option for patients with MDS and AML is allo-HSCT; however, a high frequency of relapse remains, while the role of CD8+ T cells in influencing response rates following transplantation or preventing relapses is not yet sufficiently understood. Here, CD8A is linked to acute myeloid leukemia.